Skip to main content
SpringerLink
Log in

Disorders of Lipid Metabolism

  • Chapter
  • First Online:
Pediatric Endocrinology

Abstract

Lipid physiology is a complex process involving lipid production and metabolism through exogenous, endogenous, and reverse cholesterol transport pathways. Malfunctions in these processes can result in lipid abnormalities that lead to early cardiovascular disease, premature cardiovascular death, and pancreatitis. The causes of these lipid abnormalities can be acquired, most commonly due to obesity, or genetic, as is the case in familial hypercholesterolemia. This chapter discusses normal lipid physiology, general screening guidelines, as well as the diagnosis, presentation, and management of disorders of HDL, LDL, and triglyceride metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nguyen D, Kit B, and Carroll, M. Abnormal cholesterol among children and adolescents in the United States, 2011–2014; 2015. NCHS Data Brief, 228.

    Google Scholar 

  2. Mahley RW, Weisgraber KH, Berson TP. Disorders of lipid metabolism. In: Williams textbook of endocrinology. 11th ed: Saunders Elsevier; 2008.

    Google Scholar 

  3. Chait A, Subramanian S, Brunzell JD. Genetic disorders of triglyceride metabolism. Endotext [internet]. South Dartmouth: MDText.com, Inc; 2000.

    Google Scholar 

  4. Bamba V. Update on screening, etiology and treatment of dyslipidemia in children. J Clin Endocrinol Metab. 2014;99(9):3093–102.

    Article  CAS  Google Scholar 

  5. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113–20.

    Article  Google Scholar 

  6. National Heart Lung Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2014;128(6):s213–56.

    Google Scholar 

  7. Brinton EA. Management of Hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease. Cardiol Clin. 2015;33:309–23.

    Article  Google Scholar 

  8. Watts GF, Ooi EMM, Chan DC. Demystifying the management of hypertriglyceridemia. Nat Rev Cardiol. 2013;10:648–61.

    Article  CAS  Google Scholar 

  9. Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, et al. Diagnosis and management of Type I and Type V hyperlipoproteinemia. J Atheroscler Thromb. 2012;19:1–12.

    Article  CAS  Google Scholar 

  10. Brown WV, Goldberg IJ, Young SG. JCL roundtable: hypertriglyceridemia due to defects in lipoprotein lipase function. J Clin Lipidol. 2015;9(3):274–80.

    Article  Google Scholar 

  11. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism. 2012;61:906–21.

    Article  CAS  Google Scholar 

  12. Forte TM, Ryan RO. Apolipoprotein A5: extracellular and intracellular roles in triglyceride metabolism. Curr Drug Targets. 2015;16:1274–80.

    Article  CAS  Google Scholar 

  13. Fried SK, Rao SP. Sugars, hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr. 2003;78(suppl):873S–80S.

    Article  CAS  Google Scholar 

  14. Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J. 2011;5:76–84.

    Article  CAS  Google Scholar 

  15. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48:434–41.

    Article  CAS  Google Scholar 

  16. Van De Wiel A. The effect of alcohol on postprandial and fasting triglycerides. Int J Vasc Med. 2012;2012(2012):862504. https://doi.org/10.1155/2012/862504. 4 pages.

    Article  CAS  PubMed  Google Scholar 

  17. Brunzell JD. Familial Lipoprotein Lipase Deficiency. Gene Reviews [Internet], NCBI Bookshelf, 1993–2016.

    Google Scholar 

  18. Chahal N, Manlhiot C, Wong H, McCrindle BW. Effectiveness of omega-3 polysaturated fatty acids (fish oil) supplementation for treating hypertriglyceridemia in children and adolescents. Clin Pediatr. 2014;53(7):645–51.

    Article  Google Scholar 

  19. Zhao A, Lam S. Omega-3-carboxylic acid (Epanova) for hypertriglyceridemia. Cardiol Rev. 2015;23(3):148–52.

    PubMed  Google Scholar 

  20. Soto GA, McIntyre A, Agrawal S, Bialo S, Hegele RA, et al. Severe hypertriglyceridemia due to a novel p.Q240H mutation in the lipoprotein lipase gene. Lipids Health Dis. 2015;14:102.

    Article  Google Scholar 

  21. Ahmad Z, Wilson DP. Familial Chylomicronemia syndrome and response to medium-chain triglyceride therapy in an infant with novel mutations in GPIHBP1. J Clin Lipidol. 2014;8:635–9.

    Article  Google Scholar 

  22. Manlhiot C, Larrsson P, Gurofsky RC, Smith RW, Fillingham C, et al. Spectrum and management of hypertriglyceridemia among children in clinical practice. Pediatrics. 2009;123:458–65.

    Article  Google Scholar 

  23. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016. In press.

    Google Scholar 

  24. Blackett P, Tryggestad J, Krishnan S, Li S, Xu W, Alaupovic P, et al. Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat. J Clin Lipidol. 2013;7(2):132–9.

    Article  Google Scholar 

  25. Gidding SS, Prospero C, Hossain J, Zappalla F, Balagopal P, Falkner B, et al. A double-blind randomized trial of fish oil to lower triglycerides and improve cardiometabolic risk in adolescents. J Pediatr. 2014;165:497–503.

    Article  CAS  Google Scholar 

  26. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17:387–93.

    Article  CAS  Google Scholar 

  27. Rouis M, Dugi KA, Previato L, Patterson AP, Brunzell JD, Brewer HB, et al. Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arterioscler Thromb Vasc Biol. 1997;17:1400–6.

    Article  CAS  Google Scholar 

  28. Haddley K. Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today. 2013;49(3):161–70.

    CAS  PubMed  Google Scholar 

  29. Stefanutti C, Julius U. Treatment of primary hypertriglyceridemia states- general approach and the role of extracorporeal methods. Atheroscler Suppl. 2015;18:85–94.

    Article  Google Scholar 

  30. Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense inhibition of Apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438–47.

    Article  CAS  Google Scholar 

  31. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill Medical Publishing Division; 2000. p. 2863–913.

    Google Scholar 

  32. Soufi M, Kurt B, Schweer H, Sattler AM, Klaus G, et al. Genetics and kinetics of familial hypercholesterolemia, with the special focus on FH-(Marburg) P.W566R. Atheroscler Suppl. 2009;10:5–11.

    Article  CAS  Google Scholar 

  33. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;11:1795–803.

    Article  Google Scholar 

  34. Naukkarinen J, Ehnholm C, Peltonen L. Genetics of familial combined hyperlipidemia. Curr Opin Lipidol. 2006;17:285–90.

    Article  CAS  Google Scholar 

  35. Innerarity T, Mahley R, Weisgraber K, Bersot T, Krauss R, Vega G, Grundy S, Friedl W, Davignon J, McCarthy B. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res. 1990;31:1337–49.

    CAS  PubMed  Google Scholar 

  36. Miller M, Zhan M. Genetic determinants of low high-density lipoprotein cholesterol. Curr Opin Cardiol. 2004;19:380–4.

    Article  Google Scholar 

  37. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCKS9, low LDL and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.

    Article  CAS  Google Scholar 

  38. Talmud P, Shah S, Whittall R, Futema M, Howard P, Cooper J, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolemia: a case-control study. Lancet. 2013;381(9874):1293–301.

    Article  CAS  Google Scholar 

  39. McNeal C. Lipoprotein (a):its relevance to the pediatric population. J Clin Lipidol. 2015;9:S57–66.

    Article  Google Scholar 

  40. Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson GS. Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children. Bogalusa heart study. Circulation. 1991;84:160–7.

    Article  CAS  Google Scholar 

  41. Yamauchi A, Fukuhara Y, Yamamoto S, Yano F, Takenaka M, Imai E, et al. Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Phys. 1992;263:c397.

    Article  CAS  Google Scholar 

  42. Kwiterovich PO Jr, Frederickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia); a study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974;53:1237–49.

    Article  Google Scholar 

  43. Goldber A, Hopkins P, Toth P, Ballantyne C, Rader D, Robinson J, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. Clinical Guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S1–8.

    Article  Google Scholar 

  44. Sorensen KE, Celermajer DS, Georgakopoulos D, et al. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(s) level. J Clin Invest. 1994;93:50–5.

    Article  CAS  Google Scholar 

  45. Godenber NA, Bernard TJ, Hillhouse J, et al. Elevated lipoprotein(a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematologica. 2013;98:802–7.

    Article  Google Scholar 

  46. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke. 2007;38:1959–66.

    Article  CAS  Google Scholar 

  47. Brouwers M, de Graaf J, van Greevenbroek M, Schaper N, Stehouwer CD, Stalenhoef AF. Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus. Curr Opin Lipidol. 2010;21:530–8.

    Article  CAS  Google Scholar 

  48. Gaddi A, Cicero A, Odoo FO, Poli A, Paoletti R. On behalf of the atherosclerosis and metabolic diseases study group. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007;3(6):877–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. De Bruin TWA, Castro-Cabezas M, Dallinga-Thie G and Erkelens DW. Familial combined hyperlipidemia-do we understand the pathophysiology and genetics? Lipids: Current Perspectives. London; 1996. p. 101–9.

    Google Scholar 

  50. Tammi A, Ronnemaa T, Gylling H, Rask-Nissila L, Vilkari J, Tuomimen J, et al. Plant stanol ester margarine lowers serum total and low density lipoprotein cholesterol concentrations of health children: the STRIP project. Special Turku Coronary Risk Factors Intervention Project. J Pediatr. 2000;136(4):503–10.

    Article  CAS  Google Scholar 

  51. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128S5:S213–56.

    Google Scholar 

  52. Lamber M, Lupien PJ, Gagne C, Levy E, Blaichman S, Langlois S, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Pediatrics. 1996;97:619–28.

    Google Scholar 

  53. Knipscheer HC, Boelen CC, Kastelstein JJ, van Diermen DE, Groenemeiger BE, van den Ende A, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia in children. Pediatr Res. 1993;92:78–82.

    Google Scholar 

  54. de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blinded, placebo-controlled trial with simvastatin. Circulation. 2002;106:2231–7.

    Article  Google Scholar 

  55. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJP, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27:1803–10.

    Article  CAS  Google Scholar 

  56. van der Graaf A, Nierman MC, Firth JC, Womarens KH, Marais AD, de Groot E. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Acta Paediatr. 2006;95:1461–6.

    Article  Google Scholar 

  57. Braamskamp MJ, Langslet G, McCrindle BW, Cassiman D, Francis GA, et al. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study. J Clin Lipidol. 2015;9(6):741–50.

    Article  Google Scholar 

  58. McCrindle B, Ose L, Marais D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;142:74–80.

    Article  Google Scholar 

  59. Tonstad S, Knudtzon J, Siversten M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr. 1996;129(1):42–9.

    Article  CAS  Google Scholar 

  60. Stein EA, Marais AD, Szamosi T, Raal FH, Schurr D, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156(2):231–6.

    Article  CAS  Google Scholar 

  61. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New Engl J Med. 2008;358:1431–43.

    Article  CAS  Google Scholar 

  62. Yeste D, Chacon P, Clemente M, Albisu MA, Gussingye M, Carrascosa A. Ezetimbe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab. 2009;22(6):487–92.

    Article  CAS  Google Scholar 

  63. Clauss S, Wai KM, Kavey REW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154(6):869–72.

    Article  CAS  Google Scholar 

  64. Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag. 2010;6:1023–37. https://doi.org/10.2147/VHRM.S13496.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Joshi PH, Krivitsky E, Qian Z, Vazquez G, Voros S, Miller J. Do we know when and how to lower lipoprotein(a)? Curr Treat Options Cardiovasc Med. 2010;12:396–407.

    Article  Google Scholar 

  66. Hooper AJ, Burnett JR. Update on primary Hypobetalipoproteinemia. Curr Atheroscler Rep. 2014;16:423.

    Article  Google Scholar 

  67. Welty FK. Hypobetalipoproteinemia and Abetalipoproteinemia. Curr Opin Lipidol. 2014;25(3):161–8.

    Article  CAS  Google Scholar 

  68. Miniocci I, Santini S, Cantisani V, Stitziel N, Kathiresan S, Arroyo JA, et al. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J Lipid Res. 2013;54(12):3481–90.

    Article  Google Scholar 

  69. Schaefer EJ, Santos RD, Asztalos BF, Marked HDL. Deficiency and premature coronary heart disease. Curr Opin Lipidol. 2010;21:289–97.

    Article  CAS  Google Scholar 

  70. Puntoni M, Sbrana F, Bigazzi F, Sampietro T. Tangier disease: epidemiology, pathophysiology and management. Am J Cardiovasc Drugs. 2012;12(5):303–11.

    Article  CAS  Google Scholar 

  71. Forey BA, Fry JS, Lee PN, Thornton AJ, Coombs KJ. The effect of quitting smoking on HDL-cholesterol – a review based on within-subject changes. Biomark Res. 2013;1(26):1–12.

    Google Scholar 

  72. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003;36:421–9.

    Article  CAS  Google Scholar 

  73. Kwiterovich PO Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol. 2000;86(suppl):5L–10L.

    Article  CAS  Google Scholar 

  74. Hirashio S, Ueno T, Naito T, Masaki T. Characteristic kidney pathology, gene abnormality and treatments in LCAT deficiency. Clin Exp Nephrol. 2014;18:189–93.

    Article  CAS  Google Scholar 

  75. Rader DJ, deGoma EM. Approach to the patient with extremely low HDL-cholesterol. J Clin Endocrinol Metab. 2012;97(10):3399–407.

    Article  CAS  Google Scholar 

  76. Clark RW. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. Curr Opin Pharmacol. 2006;6:162–8.

    Article  CAS  Google Scholar 

  77. Barter PJ, Nicholls SJ, Kastelein JJP, Rye KA. Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? Circulation. 2013;132:423–32.

    Article  Google Scholar 

  78. Kees Hovingh G, Ray KK, Boekholdt SM. Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? Circulation. 2013;132:433–40.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatrics, Division of Endocrinology, Baystate Children’s Hospital/UMass Medical Center-Baystate, Springfield, MA, USA

    Rushika Conroy MD, MS & Charlotte M. Boney MS, MD

  2. Pediatrics, Division of Cardiology, Baystate Children’s Hospital/UMass Medical Center-Baystate, Springfield, MA, USA

    Stewart A. Mackie MD

Authors
  1. Rushika Conroy MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stewart A. Mackie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charlotte M. Boney MS, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rushika Conroy MD, MS .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

    Sally Radovick

  2. Pediatric Endocrinology, Massachusetts General Hospital for Children, Boston, Massachusetts, USA

    Madhusmita Misra

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Conroy, R., Mackie, S.A., Boney, C.M. (2018). Disorders of Lipid Metabolism. In: Radovick, S., Misra, M. (eds) Pediatric Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-73782-9_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-73782-9_33

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-73781-2

  • Online ISBN: 978-3-319-73782-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation